EIDD-2801

TargetMol
Product Code: TAR-T8309
Supplier: TargetMol
CodeSizePrice
TAR-T8309-5mg5mg£100.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8309-10mg10mg£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8309-1mL1 mL * 10 mM (in DMSO)£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8309-25mg25mg£130.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8309-50mg50mg£170.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8309-100mg100mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8309-200mg200mg£367.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8309-500mg500mg£450.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8309-1g1g£626.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
EIDD-2801 is an isopropylester prodrug of the ribonucleoside analog N 4-hydroxycytidine (EIDD-1931) that has shown broad influenza virus and multiple coronaviruses activity.
CAS:
2349386-89-4
Formula:
C13H19N3O7
Molecular Weight:
329.309
Pathway:
Microbiology/Virology
Purity:
0.9966
SMILES:
CC(C)C(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=NO)[nH]c1=O
Target:
SARS-CoV

References

Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883. Li Y, Liu M, Yan Y, et al. Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo. Viruses. 2022, 14(6): 1142 Mart Toots , Jeong-Joong Yoon , Michael Hart ,et al.Quantitative Efficacy Paradigms of the Influenza Clinical Drug Candidate EIDD-2801 in the Ferret Model.ransl Res. 2020 Apr;218:16-28. Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: eaax5866.